301-896-3100
 |
 |
 |
 |
 |
 |
 |
Oncology Trials
The Oncology Research Program, in partnership with local oncologists, offers patients access to leading-edge clinical trials sponsored by the National Cancer Institute's Cooperative Group Program or by pharmaceutical companies. These clinical trials study investigational drugs, new combinations of standard treatments for cancer, or cancer prevention in high risk patients.
For more information, please contact Suburban Hospital Oncology Research:
Barbara Squiller |
Melissa Hyman |
For information about clinical trials, visit the National Cancer Institute.
BREAST |
|
| DFCI YOUNG AND STRONG | An Education and Supportive Care Intervention Study for Young Women with Breast Cancer |
| COH 91644 | Molecular Genetic Studies in Cancer Patients and Their Relatives |
| NCIC CTG MA.32 | A Phase III Randomized Trial of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
|
| NSABP B47 | A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer |
| S1007 | A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less.
|
| SCUSF 0806 | Phase II placebo-controlled trial of lisinopril and Coreg CR® to reduce cardiotoxicity in patients with breast cancer receiving (neo)adjuvant chemotherapy with trastuzumab (Herceptin®) |
| DMP-1 | A Study to Evaluate Different Decision-Making Approaches Used by Women Known to be at Increased Risk for Breast Cancer
|